ClinicalTrials.gg
Not yet recruitingNCT07643870Updated Jun 12, 2026

Human ADME Study of [14C]-AZD1390

A Phase 1 interventional study of AZD1390 in Advanced Solid Malignancies, sponsored by AstraZeneca. Not yet recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.

Read the detailed description

On Day 1, participants will receive one dose of [14C]-AZD1390 . Participants will be confined to the study site until Day 8.

Approximately 8 enrolled male and female participants will receive study intervention in order to achieve a minimum of 4 evaluable participants.

Participants in this study will contribute to essential knowledge that will support the development of AZD1390 as a potential treatment for GBM, a malignancy of high unmet need, while being exposed to a low level of immediate risk.

02

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • AZD1390
  • Malignancies
  • Solid tumor
  • Glioblastoma
  • Radioactivity / radiation
  • Metabolite / metabolism
  • ATM kinase inhibitor
  • Pharmacokinetics
  • Single-dose
  • ADME
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 8 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with or cytologically documented, locally advanced or solid tumour, excluding lymphoma, no active anticancer treatment,
  • performance status of 0 or 1 with no deterioration over the 2 weeks,
  • Predicted ≥ 12 weeks,
  • Adequate organ and marrow function,
  • ≥ 50 mL/min,
  • Regular bowel movements,
  • No cancer-associated cachexia (weight loss).

Exclusion criteria

Exclusion Criteria:

  • History or presence of myopathy or raised CK > 5 × at screening,
  • History of ILD, drug-induced ILD, radiation pneumonitis which required treatment,
  • History or presence of hepatic disease,
  • History of epileptic disorder or any seizure history unrelated to tumour,
  • History of MDS/AML or with features suggestive of MDS/AML,
  • Predisposition to bleeding
  • History of persisting (> 2 weeks) severe cytopenia
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection
  • History of another primary
  • Persistent toxicities ( Grade ≥ 2), excluding alopecia, caused by previous anticancer therapy,
  • Spinal cord compression or for at least 4 weeks
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    AZD1390

    Single dose of \[14C\]-AZD1390

    Drug: AZD1390

Interventions

06

What researchers measure

Primary outcomes

  1. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount excreted (Ae) (urine)

    Time frame: 6 Weeks

  2. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount excreted (CumAe) (urine)

    Time frame: 6 Weeks

  3. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount excreted (Ae) (feaces)

    Time frame: 6 Weeks

  4. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount excreted (CumAe) (feaces)

    Time frame: 6 Weeks

  5. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount excreted (Ae) (total - urine and feaces combined)

    Time frame: 6 Weeks

  6. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount excreted (CumAe) (total urine and feaces combined)

    Time frame: 6 Weeks

  7. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount (percentage) excreted (Fe) (urine)

    Time frame: 6 Weeks

  8. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount (percentage) excreted (CumFe) (urine)

    Time frame: 6 Weeks

  9. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount (percentage) excreted (Fe) (feaces)

    Time frame: 6 Weeks

  10. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount (percentage) excreted (CumAe) (feaces)

    Time frame: 6 Weeks

  11. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Amount (percentage) excreted (Fe) (total urine and faeces combined)

    Time frame: 6 Weeks

  12. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    Cumulative Amount (percentage) excreted (CumFe) (total urine and faeces combined)

    Time frame: 6 Weeks

  13. The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose

    If emesis occurs, vomitus will be analysed for total radioactivity

    Time frame: 6 Weeks

  14. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Maximum observed concentration (Cmax)

    Time frame: 6 weeks

  15. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis whole blood: Maximum observed concentration (Cmax)

    Time frame: 6 weeks

  16. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Area under the concentration-time curve from zero to infinity (AUCinf)

    Time frame: 6 weeks

  17. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Area under the concentration-time curve from zero to infinity (AUCinf)

    Time frame: 6 weeks

  18. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)

    Time frame: 6 weeks

  19. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)

    Time frame: 6 weeks

  20. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Time to reach maximum observed plasma concentration (Tmax)

    Time frame: 6 weeks

  21. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Time to reach maximum observed plasma concentration (Tmax)

    Time frame: 6 weeks

  22. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )

    Time frame: 6 weeks

  23. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )

    Time frame: 6 weeks

  24. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: 6 weeks

  25. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: 6 weeks

  26. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Mean residence time of the unchanged drug in the systemic circulation (MRT)

    Time frame: 6 weeks

  27. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Mean residence time of the unchanged drug in the systemic circulation (MRT)

    Time frame: 6 weeks

  28. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Apparent volume of distribution at steady state following extravascular administration (Vss/F)

    Time frame: 6 weeks

  29. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Apparent volume of distribution at steady state following extravascular administration (Vss/F)

    Time frame: 6 weeks

  30. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of plasma: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Time frame: 6 weeks

  31. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Analysis of whole blood: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Time frame: 6 weeks

  32. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Ratio of AUCinf of plasma AZD1390 relative to AUCinf of plasma total radioactivity

    Time frame: 6 weeks

  33. Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose

    Ratio of AUCinf of whole blood total radioactivity to AUCinf of plasma total radioactivity

    Time frame: 6 weeks

  34. Pharmacokinetic(s) of AZD1390 after a single oral dose

    Analysis of urine: Cumulative amount excreted (CumAe)

    Time frame: 6 weeks

  35. Pharmacokinetic(s) of AZD1390 after a single oral dose

    Analysis of urine: Fraction (percentage) excreted (Fe)

    Time frame: 6 weeks

  36. The distribution of total radioactivity into blood cells after a single oral dose

    Analysis of urine: Fraction (percentage) excreted (Fe)

    Time frame: 6 weeks

  37. Pharmacokinetic(s) of AZD1390 after a single oral dose

    Analysis of urine: Cumulative fraction (percentage) excreted (CumFe)

    Time frame: 6 weeks

  38. Pharmacokinetic(s) of AZD1390 after a single oral dose

    Analysis of urine: Renal clearance (CLR)

    Time frame: 6 weeks

Secondary outcomes

  1. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Maximum observed concentration (Cmax)

    Time frame: 6 weeks

  2. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Area under the concentration-time curve from zero to infinity (AUCinf)

    Time frame: 6 weeks

  3. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)

    Time frame: 6 weeks

  4. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Time to reach maximum observed plasma concentration (Tmax)

    Time frame: 6 weeks

  5. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )

    Time frame: 6 weeks

  6. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: 6 weeks

  7. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Apparent volume of distribution at steady state following extravascular administration (Vss/F)

    Time frame: 6 weeks

  8. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of plasma: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Time frame: 6 weeks

  9. The phamrmacokinetic(s) of AZD1390 metabolite

    Analysis of metabolite in plasma: parent ratio

    Time frame: 6 weeks

  10. Metabolic profiling following single oral dose of AZD1390

    Quantification and identification of major metabolites of AZD1390 in plasma and excreta.

    Time frame: 6 weeks

  11. The safety of a single dose of AZD1390

    Number of participants with AEs and SAEs and severity of AEs and SAEs (based on CTCAE v5).

    Time frame: 6 weeks

  12. The safety of a single dose of AZD1390

    Number of participants with laboratory abnormalities based on assessment of Haematology/Haemostasis (whole blood), Urinalysis (dipstick), Serology, Clinical chemistry (serum or plasma), Creatinine clearance.

    Time frame: 6 weeks

  13. The safety of a single dose of AZD1390

    Number of participants with abnormal ECG and measurement of heart rate, PR QRS, QT and QTcF intervals (in milliseconds)

    Time frame: 6 weeks

  14. The safety of a single dose of AZD1390

    Number of participants with abnormal vital signs based on assessment of body temperature, pulse rate, and blood pressure completed with automated devices.

    Time frame: 6 weeks

  15. The safety of a single dose of AZD1390

    Assessment of weight (measurement units can be variable) throughout the study.

    Time frame: 6 weeks

  16. The safety of a single dose of AZD1390

    Number of participants with abnormal physical examination based on assessment of general appearance, respiratory, cardiovascular, abdomen, skin, head and neck, lymph nodes, thyroid, musculoskeletal, and neurological systems.

    Time frame: 6 weeks

07

Study locations

2 sites
  • Research Site
    Guildford, GU2 7WG, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Apr 2028, 21 months later.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 21 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jun 12, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Apr 12, 2028
CompletionEst.
Apr 12, 2028
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07643870
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Apr 12, 2028 (estimated)
Completion
Apr 12, 2028 (estimated)
Last update
Jun 12, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD1390

Start the discussion